Information Provided By:
Fly News Breaks for May 29, 2019
CLVS
May 29, 2019 | 06:24 EDT
Goldman Sachs analyst Paul Choi downgraded Clovis Oncology to Neutral from Sell after assuming coverage of the name. He lowered his price target for the shares to $15 from $17. The stock's valuation is full relative to Rubraca's intermediate-term outlook absent clinical differentiation that supports label expansion, Choi tells investors in a research note. The analyst believes current expectations are "inflated" relative to the size of the opportunity for Rubraca in prostate cancer. His sales estimates are on average 25% below consensus estimates.
News For CLVS From the Last 2 Days
There are no results for your query CLVS